<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35814187</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-3546</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Brain, behavior, &amp; immunity - health</Title><ISOAbbreviation>Brain Behav Immun Health</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study.</ArticleTitle><Pagination><StartPage>100485</StartPage><MedlinePgn>100485</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100485</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbih.2022.100485</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Up to 37.7% of patients experience symptoms beyond 12 weeks after infection with SARS-CoV-2. To date care for people with long covid has centred around multidisciplinary rehabilitation, self care and self pacing. No pharmacotherapy has been shown to be beneficial.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">In this single centre interventional pre post study, the safety of Low Dose Naltrexone (LDN) was explored in patients with Post COVID-19 Syndrome (PCS), defined by NICE as patients with ongoing symptoms 12 or more weeks after initial infections with SARS-CoV-2 where alternative explanation for symptoms cannot be found. Patients were recruited through a Post COVID clinic, had a baseline quality of life questionnaire in symmetrical Likert format, were prescribed 2 months (1&#xa0;mg&#xa0;month one, 2&#xa0;mg&#xa0;month two) of LDN and repeated the same questionnaire at the end of the second month. Patients were monitored to adverse events.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">In total 52 patients participated of whom 40(76.9%) were female. The median age was 43.5 years(IQR 33.2-49). Healthcare workers represented the largest occupational cohort n&#xa0;=&#xa0;16(34.8%). The median time from diagnosis of COVID-19 until enrolment was 333 days (IQR 171-396.5). Thirty-eight participants (73.1%) were known to commence LDN, two of whom (5.3%) stopped taking LDN post commencement due to new onset diarrhoea and also described fatigue. In total 36(69.2%) participants completed the questionnaire at the end of the two-month period. Improvement was seen in 6 of 7 parameters measured; recovery from COVID-19, limitation in activities of daily living, energy levels, pain levels, levels of concentration and sleep disturbance (p&#xa0;&#x2264;&#xa0;0.001), improvement in mood approached but was not significant (p&#xa0;=&#xa0;0.054).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">LDN is safe in patients with PCS and may improve well-being and reduce symptomatology in this cohort. Randomised control trials are needed to further explore this.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Kelly</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHugh</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avramovic</LastName><ForeName>Gordana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>John S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Brain Behav Immun Health</MedlineTA><NlmUniqueID>101759062</NlmUniqueID><ISSNLinking>2666-3546</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long covid</Keyword><Keyword MajorTopicYN="N">Post COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SF-12</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Brendan O&#x2019;Kelly reports financial support was provided by UCD Foundation (Gilead, Pfizer, GSK Newman Fellowship). John S Lambert reports financial support was provided by Health Research Board Ireland.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>11</Day><Hour>4</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35814187</ArticleId><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="doi">10.1016/j.bbih.2022.100485</ArticleId><ArticleId IdType="pii">S2666-3546(22)00075-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altmann D.M., Boyton R.J. Decoding the unknowns in long covid. BMJ (Clinical research ed.) 2021;372 n132.</Citation><ArticleIdList><ArticleId IdType="pubmed">33541867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolton M.J., Chapman B.P., Van Marwijk H. Low-dose naltrexone as a treatment for chronic fatigue syndrome. BMJ Case Rep. 2020;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6954765</ArticleId><ArticleId IdType="pubmed">31911410</ArticleId></ArticleIdList></Reference><Reference><Citation>Care D.o.H.a.S. New research into treatment and diagnosis of long COVID. 2021. https://www.gov.uk/government/news/new-research-into-treatment-and-diagnosis-of-long-covid</Citation></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid&#x2014;mechanisms, risk factors, and management. BMJ (Clinical research ed.) 2021;374 n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., Attree E., Heightman M., Banerjee R., Banerjee A. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., You Y., Griffin N., Feng J., Shan F. Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy. Int. Immunopharm. 2018;61:178&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">29885638</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie M.R.K.L., van der Giessen J., Fuhler G.M., de Lima A., Peppelenbosch M.P., van der Ent C., van der Woude C.J. Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. J. Transl. Med. 2018;16:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5845217</ArticleId><ArticleId IdType="pubmed">29523156</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., Ahluwalia N., Bikdeli B., Dietz D., Der-Nigoghossian C., Liyanage-Don N., Rosner G.F., Bernstein E.J., Mohan S., Beckley A.A., Seres D.S., Choueiri T.K., Uriel N., Ausiello J.C., Accili D., Freedberg D.E., Baldwin M., Schwartz A., Brodie D., Garcia C.K., Elkind M.S.V., Connors J.M., Bilezikian J.P., Landry D.W., Wan E.Y. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE  . 2021. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19.https://www.nice.org.uk/guidance/ng188 NICE guideline [NG188]</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten D.K., Schultz B.G., Berlau D.J. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, crohn's disease, and other chronic pain disorders. Pharmacotherapy. 2018;38:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">29377216</ArticleId></ArticleIdList></Reference><Reference><Citation>Raknes G., Simonsen P., Sm&#xe5;brekke L. The effect of low-dose naltrexone on medication in inflammatory bowel disease: a quasi experimental before-and-after prescription database study. Journal of Crohn's and Colitis. 2018;12:677&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5972567</ArticleId><ArticleId IdType="pubmed">29385430</ArticleId></ArticleIdList></Reference><Reference><Citation>Raknes G., Sm&#xe5;brekke L. Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS One. 2019;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6375629</ArticleId><ArticleId IdType="pubmed">30763385</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dowds J., O'Brien K., Sheill G., Dyer A.H., O'Kelly B., Hynes J.P., Mooney A., Dunne J., Ni Cheallaigh C., O'Farrelly C., Bourke N.M., Conlon N., Martin-Loeches I., Bergin C., Nadarajan P., Bannan C. Persistent poor Health after COVID-19 is not associated with respiratory complications or initial disease severity. Annals of the American Thoracic Society. 2021;18:997&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456724</ArticleId><ArticleId IdType="pubmed">33413026</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dyer A.H., Jones K., Dunne J., Mooney A., Gaffney F., O'Connor L., Leavy D., O'Brien K., Dowds J., Sugrue J.A., Hopkins D., Martin-Loeches I., Ni Cheallaigh C., Nadarajan P., McLaughlin A.M., Bourke N.M., Bergin C., O'Farrelly C., Bannan C., Conlon N. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15 e0240784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Turel A.P., Oh K.H., Zagon I.S., McLaughlin P.J. Low dose naltrexone for treatment of multiple sclerosis: a retrospective chart review of safety and tolerability. J. Clin. Psychopharmacol. 2015;35:609&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">26203498</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M.E.J., Chadeau-Hyam M., Riley S., Darzi A., Cooke G., Ward H., Elliott P.  2021. Persistent Symptoms Following SARS-CoV-2 Infection in a Random Community Sample of 508,707 People.https://spiral.imperial.ac.uk/handle/10044/1/89844 Imperial College London.</Citation></Reference><Reference><Citation>WHO  . 2022. WHO Coronavirus (COVID-19) Dashboard.https://covid19.who.int/</Citation></Reference><Reference><Citation>Yong S.J. Persistent brainstem dysfunction in long-COVID: a hypothesis. ACS Chem. Neurosci. 2021;12:573&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">33538586</ArticleId></ArticleIdList></Reference><Reference><Citation>Younger J., Parkitny L., McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin. Rheumatol. 2014;33:451&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3962576</ArticleId><ArticleId IdType="pubmed">24526250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>